mission shrna library, page-3

eieio, Sigma-Aldrich bought the exclusive licence for all non-therapeutic ddRNAi some years back. So, if MIT produced MISSION shRNA using BLT's patented technology and make money selling it, presumably they would require a sub-licence from Sigma-Aldrich. They probably have a quid pro-quo type of arrangement.

BLT in turn receive royalties from Sigma-Aldrich on sub-licences they issue and royalties on sales. But, given the income over the last few years, it appears to be minimal.